Press Release

Press Release
RepliCel to Meet with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Process
Phase II Dose Ranging Trial Planned for 2013 VANCOUVER, BC – February 4, 2013 –...
Press Release
RepliCel Completes First Pre-Filing Review with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Pro
Phase II Dose Ranging Trial on its Hair Cell Replication Technology Expected to Commence Mid-2013...
Press Release
RepliCel’s Common Shares Listed on CNSX
VANCOUVER, BC – October 1, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...
Press Release
RepliCels Chief Scientific Officer Updates European Hair Research Society on RepliCels TS001-2009 First-in-man Clinical Trial
VANCOUVER, BC – June 26, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...
Press Release
Further Analysis Reveals Double Digit Hair Growth in RepliCels First-in-man Clinical Trial
Company Takes Next Steps for Phase IIb Dosing Trial VANCOUVER, BC – May 17, 2012...
Press Release
RepliCel Releases Positive Results from the Interim Analysis of Data from its First-in-man TS001-2009 Clinical Trial
VANCOUVER, BC – May 2, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.